Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations

被引：0
|
作者：
Ni, Ting
Huo, Tongxin
Zhang, Yawen
Wang, Jingjing
Liu, Gaoxiang
Shi, Wenting
Gu, Qingyang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1946
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1946
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
    Notario, Lucia
    Cucurull, Marc
    Cerda, Gabriela
    Sanz, Carolina
    Carcereny, Enric
    Munoz-Marmol, Ana
    Hernandez, Ainhoa
    Domenech, Marta
    Moran, Teresa
    Sanchez-Cespedes, Montse
    Costa, Marta
    Mate, Jose-Luis
    Esteve, Anna
    Saigi, Maria
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
    Loong, H.
    Du, N.
    Cheng, C.
    Lin, H.
    Guo, J.
    Lin, G.
    Li, M.
    Jiang, T.
    Shi, Z.
    Cui, Y.
    Jin, X.
    Yao, J.
    Xing, Y.
    Yao, M.
    Wang, K.
    Mok, T.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S426 - S426
  • [23] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [24] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [25] Overcoming adaptive resistance to KRAS G12C inhibitors
    Adachi, Yuta
    Niitsu, Hiroaki
    Yamaguchi, Rui
    Ebi, Hiromichi
    CANCER SCIENCE, 2024, 115 : 110 - 110
  • [26] Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
    Wang, W.
    Lim, S. M.
    Yu, M. R.
    Cho, B. C.
    Chen, C.
    Wu, W.
    Zhang, J.
    Chen, Z. J.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
  • [27] KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
    Koga, Takamasa
    Suda, Kenichi
    Fujino, Toshio
    Ohara, Shuta
    Hamada, Akira
    Nishino, Masaya
    Chiba, Masato
    Shimoji, Masaki
    Takemoto, Toshiki
    Arita, Takeo
    Gmachl, Michael
    Hofmann, Marco H.
    Soh, Junichi
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1321 - 1332
  • [28] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [29] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [30] AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
    Wu, Lei-Lei
    Jiang, Wen-Mei
    Liu, Zhi-Yuan
    Zhang, Yi-Yi
    Qian, Jia-Yi
    Liu, Yu'e
    Huang, Yang-Yu
    Li, Kun
    Li, Zhi-Xin
    Ma, Guo-Wei
    Xie, Dong
    DISCOVER ONCOLOGY, 2023, 14 (01)
12345